InNexus makes new appointment to board of directors
This article was originally published in Scrip
Executive Summary
InNexus Biotechnology, a drug development company commercialising next-generation monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology, has appointed David Warden to its board of directors. Mr Warden was a founding partner of Yetter, Warden & Coleman, and brings 23 years' experience in practice to the role, including cases of antitrust, patents and business and technology litigation. His appointment marks a further move by InNexus to increase its intellectual property practice; it previously appointed Gilbert Gabo as vice-president of operations and director of legal affairs. Mr Gabo brought a decade of operations experience, as well as experience as a practising patent attorney.